TY - JOUR
TI - European society of hypertension position paper on renal denervation 2018
AU - Schmieder, R.E.
AU - Mahfoud, F.
AU - Azizi, M.
AU - Pathak, A.
AU - Dimitriadis, K.
AU - Kroon, A.A.
AU - Ott, C.
AU - Scalise, F.
AU - Mancia, G.
AU - Tsioufis, C.
JO - JOURNAL OF HYPERTENSION
PY - 2018
VL - 36
TODO - 10
SP - 2042-2048
PB - Lippincott Williams and Wilkins
SN - -
TODO - 10.1097/HJH.0000000000001858
TODO - antihypertensive agent;  beta adrenergic receptor blocking agent;  diuretic agent, Article;  blood pressure;  cardiovascular disease;  cerebrovascular accident;  drug monitoring;  heart failure;  human;  hypertension;  incidence;  kidney denervation;  medical society;  priority journal;  proof of concept;  protocol compliance;  sympathetic tone;  Europe;  hypertension;  innervation;  kidney;  kidney artery;  medical society;  pathophysiology;  practice guideline;  procedures;  randomized controlled trial (topic);  sympathectomy, Europe;  Humans;  Hypertension;  Kidney;  Randomized Controlled Trials as Topic;  Renal Artery;  Societies, Medical;  Sympathectomy
TODO - This ESH update was deemed necessary with the publication of new results of sham-controlled randomized blinded prospective trials with renal denervation (RDN). Proof of concept studies and first randomized trials (some were sham-controlled) displayed discrepant results about the efficacy of RDN. Three sham-controlled randomized trials of the 2.0 generation yielded now similarity in the average blood pressure decrease following RDN. Reduction of ambulatory blood pressure was approximately 5 to 7 mmHg and of office blood pressure 10 mmHg. Such a decrease in blood pressure by pharmacologic therapy has been found to be associated with lower incidence of cardiovascular events in particular with respect to heart failure and stroke by roughly 25%. Nevertheless, some questions about renal denervation are unanswered. The heterogeneity of the blood pressure-lowering response point to the clinical need to identify predictors for efficacy, and questions on long-term safety could not have been answered due to the short duration of the sham-controlled randomized clinical trials. © 2018 Wolters Kluwer Health, Inc.
ER -